Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
abscess, intracerebral
acute disseminated encephalomyelitis
adverse drug reaction
Alzheimer's disease
Alzheimer's disease, diagnosis of
Alzheimer's disease, preclinical
amyloid beta protein
amyloid imaging
amyloid plaques
angiitis, isolated of CNS
antibodies to myelin basic protein
antibodies to myelin oligodendrocyte glycoprotein
antimyelin antibodies
asymptomatic
ataxia
autoantibodies
autoimmune disease
axonal degeneration
axonal transection
B cell lymphocytes
Barkhof MR criteria for MS
BCG vaccination
BENEFIT study
biologic markers
brain atrophy
brain biopsy
brain volume
brainstem
brainstem, infarction of
brainstem, lesion of
carcinoma
carcinoma of breast
carotid artery occlusion, intracranial
CAT scan
CAT scan, abnormal
CAT scan, cerebrovascular disease
CAT scan, dense artery sign
CAT scan, early changes in CVA
CAT scan, emission
CAT scan, emission, abnormal
CAT scan, mass effect on
CAT scan, ring sign
central nervous system, infection of
cerebellar infarction
cerebellar lesion
cerebral arteries
cerebral infarction
cerebral infarction, hemorrhagic
cerebral ischemia
cerebrospinal fluid
cerebrospinal fluid, abnormal
cerebrospinal fluid, biochemical markers of CNS disease
cerebrospinal fluid, oligoclonal IgG in
cerebrospinal fluid, protein of
cerebrovascular accident
cerebrovascular accident, acute management of
cerebrovascular accident, arterial occlusion, location
cerebrovascular accident, prognosis in
cerebrovascular accident, recurrent
cerebrovascular accident, severity
cerebrovascular accident, thrombolytic agents in treatment
cerebrovascular accident, volume
cerebrovascular accident, work up for
cerebrovascular accident, young adult
children
Clinical Pathologic Conference(C.P.C.)
cognition
complications
controversies in neurology
cop 1
corneal dystrophy
corpus callosum
corpus callosum, lesion of
cyclophosphamide
degenerative diseases of CNS
dementia
dementia, diagnostic evaluation of
dementia, early detection
dementia, presenile
dementia, rapidly progressive
dementia, screening for
demyelinating disease
diabetes insipidus
diagnostic criteria
disability rating scale, neurological
disability, neurological
disease modifying agents
efficacy
encephalitis
encephalitis, viral
encephalomyelitis, postinfectious
encephalopathy, Hashimoto's
encephalopathy, metabolic
endovascular therapy
enzyme, defect
Epstein-Barr virus
evoked potentials
Fabry's disease
falling
fever
fibrinolytic agents
fibrinolytic agents, complications
fingolimod
florbetapir
flu-like illness
fourth ventricle, shift of
fumarate
gadolinium
gait disorder
gammaglobulin therapy, intravenous
genetic neurologic disorders
head injury
hearing loss
hearing loss, sudden, unilateral
hemiparesis
heralding manifestation
herpes simplex encephalitis
herpes virus
herpes virus infection
hippocampal atrophy
hippocampus
hydrocephalus
hydrocephalus, exvacuo
hypertension
immunomodulation
immunosuppressive agents
immunotherapy
infection
interferon
interferon beta 1-a
interferon beta 1-b
internal carotid artery
intracerebral hemorrhage
intravenous
ischemic penumbra
Jakob-Creutzfeldt disease
laquinimod
L-dopa
leukoencephalopathy
leukopenia
liver function enzymes
lobar atrophy
Marburg's disease
McDonald criteria for MS
medulla oblongata, infarction of
memory, impairment of
mild cognitive impairment
misdiagnosis
mitoxantrone
monoclonal antibodies
MRI
MRI, abnormal
MRI, ADC maps
MRI, angiography
MRI, cerebrovascular disease
MRI, contrast enhanced
MRI, demyelinating disease
MRI, diffusion weighted
MRI, early changes in CVA
MRI, false negative
MRI, fast
MRI, field strength
MRI, field strength, high
MRI, functional
MRI, incidental finding
MRI, lesion burden
MRI, mass effect on
MRI, negative
MRI, optic nerve
MRI, perfusion
MRI, ring sign
MRI, serial
MRI, spinal cord
MRI, volumetry
MRS
multiple sclerosis
multiple sclerosis, acute
multiple sclerosis, asymptomatic
multiple sclerosis, children
multiple sclerosis, chronic progressive
multiple sclerosis, clinical patterns
multiple sclerosis, conversion to clinically definite
multiple sclerosis, diagnosis of
multiple sclerosis, diagnostic criteria
multiple sclerosis, differential diagnosis of
multiple sclerosis, disability status scale
multiple sclerosis, early onset
multiple sclerosis, etiology of
multiple sclerosis, misdiagnosis
multiple sclerosis, monosymptomatic
multiple sclerosis, MRI conversion
multiple sclerosis, MRI criteria
multiple sclerosis, pathogenesis
multiple sclerosis, preclinical
multiple sclerosis, presenting manifestations
multiple sclerosis, prognosis
multiple sclerosis, prophylaxsis
multiple sclerosis, radiologically isolated syndrome
multiple sclerosis, relapsing
multiple sclerosis, risk factors for
multiple sclerosis, secondary progressive
multiple sclerosis, spinal form
multiple sclerosis, treatment of
multiple sclerosis, treatment of, first attack
N-acetyl-L-aspartic acid
natalizumab
neoplasm, intracranial
neoplasm, primary intracerebral
neoplasm, primary intracranial
neoplasm, primary of CNS
neoplasm, primary of CNS-children
neurologic disease, diagnoses of
neurologic signs
neurologic symptoms
neuropathology
neuroprotective agents
neurosyphilis
NIH stroke scale
nystagmus
ocrelizumab
old age, neurology of
optic nerve, lesion of
optic neuritis
optic neuritis, bilateral
optic neuritis, children
optic neuritis, etiology of
optic neuritis, recurrent
optic neuritis, treatment of
optical coherence tomography
Parkinson disease
Parkinson disease, late onset
Parkinson disease, treatment of
Parkinson disease, young onset
periventricular leukomalacia
Pittsburgh Compound B
placebo
pons, infarction of
posterior cerebral artery territory infarction
posterior fossa
posterior fossa, lesion of
practice guidelines
preclinical
pregnancy, neurologic complications in
prevention of neurologic disorders
prion disease
prognosis
protein 14-3-3, cerebrospinal fluid
pseudotumor
rapidly progressing neurologic illness
remote effect of cancer on the nervous system
revascularization, surgical
review article
risk factors
safety
sarcoidosis, CNS
screening
seizure
seizure, children
sensorineural hearing loss
serologic testing
single photon emission computed tomography
slurred speech
somnambulism
spinal cord
spinal cord, enlargement
spinal cord, intramedullary cyst of
spinal cord, lesion of
spinal cord, neoplasm
spinal cord, neoplasm, infants and children
steroid
steroid therapy, CNS treatment and complications with
stroke disability scale
symmetric brain lesions
symptomatic
syphilis, diagnosis and treatment
syphilis, neurologic complications with
syringomyelia
T lesion of MCA-ICA
temporal lobe, atrophy
thyroiditis
tinnitus
tissue plasminogen activator, intravenous
toxic encephalopathy
transient ischemic attack
treatment of neurologic disorder
uremia
urinary incontinence
urinary retention
ventricular enlargement
vertebral-basilar insufficiency
vertigo
vertigo, episodic
viral infection
viral infection, CNS
viral infection, reactivation
visual evoked response
West Nile fever
white matter disease
white matter disease, periventricular
Showing articles 0 to 50 of 4313 Next >>

The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024

Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023

Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018

Inclusion of Optic Nerve Involvement in Dissemination in Space Criteria for Multiple Sclerosis
Neurol 91:e1130-e1134,545, Brownlee, W.J.,et al, 2018

Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018

Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients with a Typical Clinically Isolated Syndrome
JAMA Neurol 75:1392-1398, Van Der Vuurst De Vries, R.M.,et al, 2018

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014

Addition of Hyperacute MRI Aids in Patient Selection, Decreasing the Use of Endovascular Stroke Therapy
Stroke 45:467-472, Wisco, D.,et al, 2014

Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013

An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013

Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013

Location of Brain Lesions Predicts Conversion of Clinically Isolated Syndromes to Multiple Sclerosis
Neurol 80:234-241, Giorgio, A.,et al, 2013

Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012

Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012

Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011

Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011

MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011

Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010

Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010

A Comparison of MRI Criteria for Diagnosing Pediatric ADEM and MS
Neurol 74:1412-1415, 1404, Ketelslegers,I.A., et al, 2010

Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009

Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study
Arch Neurol 66:1345-1352, Moraal,B.,et al, 2009

Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe study): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 374:1503-1511, 1475, Martinelli,G.,et al, 2009

Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009

Incidental MRI Anomalies Suggestive of Multiple Sclerosis: The Radiologically Isolated Syndrome
Neurol 72:800-805,780, Okuda,D.T.,et al, 2009

Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009

MRI in the Diagnosis of Pediatric Multiple Sclerosis
Neurol 72:961-967, Callen,D.J.A.,et al, 2009

A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis
Arch Neurol 66:587-592, Rovira,A.,et al, 2009

Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009

Real-Life Impact of Early Interferon� Therapy in Relapsing Multiple Sclerosis
Ann Neurol 66:513-520, Trojano,M.,et al, 2009

Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008

Do Oligoclonal Bands Add Information to MRI in First Attacks of Multiple Sclerosis?
Neurol 70:1079-1083,1059, Tintore,M.,et al, 2008

Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008

Hyperdense Internal Carotid Artery Sign: A CT Sign of Acute Ischemia
Stroke 39:2011-2016, Ozdemir,O.,et al, 2008

Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008

Unexpected Multiple Sclerosis: Follow-Up of 30 Patients With Magnetic Resonance Imaging and Clinical Conversion Profile
JNNP 79:195-198,112, Lebrun,C.,et al, 2008

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Natural History of Multiple Sclerosis with Childhood Onset
NEJM 356:2603-2613, Renoux,C.,et al, 2007

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Does High-Field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis
AJNR 27:1794-1798, Wattjes,M.P.,et al, 2006

Baseline MRI Predicts Future Attacks and Disability in Clinically Isolated Syndromes
Neurol 67:968-972, Tintore,M.,et al, 2006

Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006

Dementia and White-Matter Demyelination in Young Patient With Neurosyphilis
Lancet:368:2258, Brinar,V.V. &Habek,M., 2006

Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006



Showing articles 0 to 50 of 4313 Next >>